| 英文摘要 |
Meningioma represents a commonly diagnosed central nervous system neoplasm in Taiwan. Etiologically, this type of tumor has been linked to mutations in the connective tissue adjacent to the brain. Based on the World Health Organization’s classification system, meningiomas are categorized into three groups, reflecting their behavior: benign, atypical, and malignant. The primary therapeutic modalities for malignant meningioma encompass surgical resection and radiation therapy. Yet, advancements in pharmacological interventions remain scarce. In the clinical realm, recurrence following conventional surgery, radiotherapy, or adjunctive treatments is not an uncommon for patients with malignant meningioma. Due to the dearth of potent salvage therapies, tumor recurrence frequently results in mortality. In 2017, the boron neutron capture therapy (BNCT) neuro-oncology teams of Taipei Veterans General Hospital and Tsinghua University pioneered a unique therapy model for recurrent malignant brain tumors (including meningioma). Employing this novel targeted particle radiation therapy, patients who have failed conventional therapy can achieve effective tumor control. Furthermore, the comprehensive team not only provided high-quality medical interventions, but also afforded holistic care to patients both physically and mentally. In this report, the disease course of a female patient with recurrent malignant meningioma is depicted. She was offered BNCT, and neither cancer recurrence nor serious complications were presented after treatment with more than one year of follow-up. Such a commendable, high-caliber, and efficacious therapeutic modality certainly merits extensive investigation and endorsement. |
本站僅提供期刊文獻檢索。
